A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

NCT03785925 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasm
Neoplasm Metastasis

Interventions

BIOLOGICAL: Bempegaldesleukin
BIOLOGICAL: Nivolumab

Sponsor

Nektar Therapeutics

Collaborators

[object Object]